<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Ligand Pharmaceuticals Incorporated — News on 6ix</title>
    <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated</link>
    <description>Latest news and press releases for Ligand Pharmaceuticals Incorporated on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 07 May 2026 11:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/ligand-pharmaceuticals-incorporated" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835913e78dffbe2df1025f3.webp</url>
      <title>Ligand Pharmaceuticals Incorporated</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated</link>
    </image>
    <item>
      <title>Ligand Reports First Quarter 2026 Financial Results</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-reports-first-quarter-2026-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-reports-first-quarter-2026-financial-results</guid>
      <pubDate>Thu, 07 May 2026 11:00:00 GMT</pubDate>
      <description>First quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution from Pending XOMA Royalty Acquisition Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three months ended March 31, 2026, and provided an operating forecas</description>
    </item>
    <item>
      <title>Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/orchestra-biomed-receives-dollar15-million-investment-from-ligand-under-previously-announced-strategic-financing-agreement-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/orchestra-biomed-receives-dollar15-million-investment-from-ligand-under-previously-announced-strategic-financing-agreement-1</guid>
      <pubDate>Wed, 06 May 2026 12:01:00 GMT</pubDate>
      <description>$15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty interest in Orchestra BioMed’s future revenue as well as equityFunding supports continued execution of Orchestra BioMed’s pivotal trials for Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) and Virtue Sirolimus AngioInfusion Balloon (“Virtue SAB”) This payment, together with a $20 million</description>
    </item>
    <item>
      <title>Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-to-acquire-xoma-royalty-further-accelerating-profit-growth-and-strengthening-ligands-position-as-a-leading-biopharma-royalty-aggregator</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-to-acquire-xoma-royalty-further-accelerating-profit-growth-and-strengthening-ligands-position-as-a-leading-biopharma-royalty-aggregator</guid>
      <pubDate>Mon, 27 Apr 2026 11:00:00 GMT</pubDate>
      <description>Transaction expands Ligand’s royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand’s long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden patient access and improve lives Acquisition is expected to be immediately accretive to Ligand adjusted EPS; Ligand increases 2026 adjusted EPS guidance to $8.50-$9.501 and expects the transaction to be accretive by $1.50</description>
    </item>
    <item>
      <title>Ligand to Report First Quarter 2026 Financial Results on May 7, 2026</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-to-report-first-quarter-2026-financial-results-on-may-7-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-to-report-first-quarter-2026-financial-results-on-may-7-2026</guid>
      <pubDate>Wed, 22 Apr 2026 11:00:00 GMT</pubDate>
      <description>JUPITER, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026. The company will hold a conference call beginning at 8:30 a.m. Eastern time to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, May 7, 2026 Time: 8:30 a.m. Eastern time Conference Call: United States (Local): +1 (585) 542-9983 United</description>
    </item>
    <item>
      <title>Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-partner-travere-therapeutics-receives-full-fda-approval-for-filsparir-sparsentan-in-fsgs</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-partner-travere-therapeutics-receives-full-fda-approval-for-filsparir-sparsentan-in-fsgs</guid>
      <pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
      <description>FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data</description>
    </item>
    <item>
      <title>Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-advances-strategic-growth-with-expanded-and-strengthened-business-development-team</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-advances-strategic-growth-with-expanded-and-strengthened-business-development-team</guid>
      <pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
      <description>JUPITER, Fla., March 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed two leading healthcare</description>
    </item>
    <item>
      <title>Ligand Reports Fourth Quarter and Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-reports-fourth-quarter-and-full-year-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
      <pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
      <description>Robust financial performance driven by full year 2025 royalty revenue growth of 48% Reiterating 2026 financial guidance of $245-$285 million in revenues and</description>
    </item>
    <item>
      <title>Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-report-fourth-quarter-full-120000324</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-report-fourth-quarter-full-120000324</guid>
      <pubDate>Thu, 12 Feb 2026 12:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, February 26, 2026 Time: 8:30 AM Eastern Time Conference Call:(800) 715-9871 (U.S. &amp; Canada)(646)</description>
    </item>
    <item>
      <title>Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-present-oppenheimer-36th-annual-healthcare-life-sciences-conference-2026-02-04</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-present-oppenheimer-36th-annual-healthcare-life-sciences-conference-2026-02-04</guid>
      <pubDate>Wed, 04 Feb 2026 05:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis</description>
    </item>
    <item>
      <title>Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-hosts-2025-investor-day-and-introduces-2026-guidance-2025-12-09</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-hosts-2025-investor-day-and-introduces-2026-guidance-2025-12-09</guid>
      <pubDate>Tue, 09 Dec 2025 05:00:00 GMT</pubDate>
      <description>Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of</description>
    </item>
    <item>
      <title>Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-reports-third-quarter-2025-financial-results-and-raises-guidance-2025-11-06</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-reports-third-quarter-2025-financial-results-and-raises-guidance-2025-11-06</guid>
      <pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
      <description>Third quarter performance driven by strong portfolio royalty revenue growth of 47% 2025 full year revenue guidance increased to $225 million - $235 million</description>
    </item>
    <item>
      <title>Ligand to Participate in November Investor Conferences</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-participate-november-investor-conferences-2025-10-30</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-participate-november-investor-conferences-2025-10-30</guid>
      <pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis</description>
    </item>
    <item>
      <title>Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-report-third-quarter-2025-financial-results-november-6-2025-2025-10-23</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-report-third-quarter-2025-financial-results-november-6-2025-2025-10-23</guid>
      <pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2025</description>
    </item>
    <item>
      <title>Ligand to Host Investor Day on December 9, 2025</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-host-investor-day-december-9-2025-2025-10-16</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-host-investor-day-december-9-2025-2025-10-16</guid>
      <pubDate>Thu, 16 Oct 2025 04:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take</description>
    </item>
    <item>
      <title>Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-partner-sq-innovation-receives-fda-approval-lasixr-onyu-home-treatment-edema</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-partner-sq-innovation-receives-fda-approval-lasixr-onyu-home-treatment-edema</guid>
      <pubDate>Thu, 09 Oct 2025 04:00:00 GMT</pubDate>
      <description>Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th</description>
    </item>
    <item>
      <title>Ligand to Participate in September Investor Conferences</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-participate-september-investor-conferences-2025-08-19</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-participate-september-investor-conferences-2025-08-19</guid>
      <pubDate>Tue, 19 Aug 2025 04:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis</description>
    </item>
    <item>
      <title>Ligand Announces Closing of Convertible Senior Notes Offering</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-announces-closing-convertible-senior-notes-offering-2025-08-14</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-announces-closing-convertible-senior-notes-offering-2025-08-14</guid>
      <pubDate>Thu, 14 Aug 2025 04:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today that it completed its</description>
    </item>
    <item>
      <title>Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-announces-pricing-400-million-convertible-senior-notes-offering-2025-08-12</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-announces-pricing-400-million-convertible-senior-notes-offering-2025-08-12</guid>
      <pubDate>Mon, 11 Aug 2025 04:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today the pricing of $400.0 million</description>
    </item>
    <item>
      <title>Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-announces-proposed-offering-400-million-convertible-senior-notes-due-2030-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-announces-proposed-offering-400-million-convertible-senior-notes-due-2030-2025</guid>
      <pubDate>Mon, 11 Aug 2025 04:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $400.0</description>
    </item>
    <item>
      <title>Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-reports-second-quarter-2025-financial-results-and-raises-guidance-2025-08-07</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-reports-second-quarter-2025-financial-results-and-raises-guidance-2025-08-07</guid>
      <pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
      <description>Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million</description>
    </item>
  </channel>
</rss>